Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 135.85% from the company’s previous close.

A number of other research firms also recently weighed in on ABEO. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research report on Tuesday. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 10th.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $6.36 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 7.48 and a quick ratio of 7.48. The company’s fifty day moving average price is $5.99 and its two-hundred day moving average price is $5.17. The firm has a market capitalization of $260.52 million, a P/E ratio of -1.99 and a beta of 1.53. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.42). On average, research analysts anticipate that Abeona Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new stake in Abeona Therapeutics in the first quarter worth $91,000. Bank of New York Mellon Corp grew its position in shares of Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 2,434 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter worth about $1,732,000. abrdn plc lifted its position in Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.